Gordon Schooley Joins Astralis' Board of Directors FAIRFIELD, N.J., April 26 /PRNewswire-FirstCall/ -- Astralis Ltd (OTC:ASTR) (BULLETIN BOARD: ASTR) announced the appointment of Gordon Schooley, Ph.D. to its Board of Directors. Dr. Schooley will also serve as a member of Astralis' Medical Advisory Board. Schooley, a recognized scientist and clinical expert, is currently the Chief Scientific Officer of SkyePharma, PLC. "It is a pleasure to welcome Dr. Schooley to the Astralis Board of Directors. His accomplished background over a period of 33 years in the pharmaceutical field, including his extensive clinical and product development experience will provide valuable expertise to Astralis, and will complement the Astralis team nicely," stated James Sharpe, Chief Executive Officer. "The addition of Dr. Schooley to the Board also signifies the resurgence of the cooperation between Astralis and SkyePharma. We are pleased to have him on our Board, and look forward to his contributions." Jose O'Daly, M.D., Ph.D., Chief Scientific Officer and Chairman of the Board of Astralis, said, "We are very pleased to see the addition of Dr. Schooley, whom I have known since 2001, to our Board of Directors. His appointment demonstrates the commitment of both Astralis and SkyePharma to continuing the development of Psoraxine, our product for the treatment of Psoriasis. We also welcome Dr. Schooley's advice and guidance as we work to develop the other products in our pipeline." Dr. Schooley received his BS and MS degrees in Business and Statistics from Brigham Young University and his Doctorate degree in Biostatistics from The University of Michigan School of Public Health. This press release may contain forward-looking statements regarding Astralis Ltd. Clinical results may differ materially from those described in the press release as a result of a number of factors. There can be no assurance that Psoraxine(R) will be successfully developed or manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of this product will be achieved. Astralis Ltd undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release. Notes to the Editor Astralis Ltd, a biotechnology company based in New Jersey, focuses on the research and development of novel treatments for immune system disorders and skin diseases. Psoraxine(R), the company's first product candidate, is an innovative drug under development for psoriasis, and is based on the discovery of a proprietary protein extract. For more information, visit Astralis' web site at http://www.astralisltd.com/. Psoriasis Psoriasis is a chronic, genetically based remitting and relapsing scaly and inflammatory skin disorder that affects approximately 3% of the world's population. Psoriasis symptoms result from the overproduction of skin induced by blood cells associated with the immune system. These blood cells are over-stimulated and act as though the skin was damaged, manufacturing skin cells at a much faster rate than is required by undamaged skin. The overproduction of skin can cause a range of symptoms including itchy rash like patches, painful pustules and massive inflammation. Additional information can be obtained from: US National Psoriasis Foundation at http://www.psoriasis.org/ International Federation of Psoriasis Associations at http://www.ifpa-pso.org/ DATASOURCE: Astralis Ltd CONTACT: Astralis Ltd, +1-973-227-7168, or fax, +1-973-227-7169, Web site: http://www.astralisltd.com/

Copyright